Trial supplies of candidate breast cancer radio-mAb still stable after 5 years says study

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Cancer, Epidermal growth factor receptor

212Pb-TCMC-trastuzumab stable after 5 years
212Pb-TCMC-trastuzumab stable after 5 years
Trial supplies of a radio-immunotherapy drug made by Areva Med in compliance with GMP are stable five years after they were produced according to the results of new analysis.

The findings – published in the journal Pharmaceuticals​ – show that a candidate drug called 212Pb-TCMC-trastuzum – which combines a tumour targeting antibody attached to a radioactive lead marker – has remained within specifications for 10 of the 11 criteria tested for a period five years.

Only one criterion – protein concentration – fell outside specification, varying by 0.01mg/mL after 48 months.

Also results from ion-exchange chromatography testing and a competitive radioimmunoassay suggested the drug may be changing, although both measurements are still within specified limits.

The authors concluded that - while the protein concentration results merit further study - the conjugated molecule have remained stable and functional since being manufacturered by Areva Med and Dallas-based ligand contractor Macrocyclics.

The authors wrote that: “The immunoconjugate, the TCMC-trastuzumab, has proven to be a robust construct​.”

They added that: “Considering the resources financial, time and personnel required to translate a radioimmunoconjugate from the bench to bedside through to treating patients, these results are certainly encouraging​.”

The drug also performed well in the trial, which was a Phase I study of the safety, distribution, pharmacokinetics, immunogenicity and tumor response in patients with human epidermal growth factor receptor type 2 (HER-2)–expressing breast cancer.

According to preliminary results​ patients with carcinomatosis experienced minimal agent-related toxicity after five doses of 212​Pb-TCMC-trastuzumab.

Areva Med – which is a subsidiary of French nuclear and renewable energy firm Areva – acquired Macrocyclics in 2011.

Related news

Show more

Related products

show more

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 18-Apr-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us

Products

View more

Webinars